此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

2026年11月13日 更新者:Finzelberg GmbH & Co. KG

The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.

研究概览

详细说明

This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.

Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.

Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.

Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.

研究类型

介入性

注册 (估计的)

78

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • RLP
      • Andernach、RLP、德国、56626
        • Finzelberg
      • Cork、爱尔兰
        • Atlantia Clinical Trials
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Be able to give written informed consent.
  2. Be between 18-70 years of age.
  3. BMI between 18.5 and 30.0 kg/m2
  4. Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
  5. Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.

Exclusion Criteria:

  1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.

  2. Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.

  3. Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)

  4. Participants that are habitual smokers or vapers

  5. High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day

  6. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  7. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:

    1. Uncontrolled hypertension
    2. Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
    3. Diagnosed cognitive impairment
    4. Type I or II diabetes
    5. Clinically significant cardiovascular, liver and renal disease
    6. Diagnosed gastrointestinal conditions (IBD, coeliac disease)
  8. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:

    a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)

  9. Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:

    1. Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
    2. Products containing Sideritis, Sage, Thymus and Oregano
  10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

  11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo supplement containing carrier material only

Placebo supplement containing carrier material only

实验性的:Siderits

Sideritis supplement administered at an estimated daily dose

Sideritis scardica preparation (Greek Mountain Tea)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
大体时间:Baseline, day 1, day 7

Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)

Baseline, day 1, day 7

次要结果测量

结果测量
措施说明
大体时间
Cognitive performance during the test called Choice Reaction Time (CRT)
大体时间:Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%)

Baseline, day 1, day 7
Cognitive Performance: Rapid Visual Information Processing (RVIP)
大体时间:Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits)

Baseline, day 1, day 7
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
大体时间:Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenation
大体时间:Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
大体时间:Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
大体时间:Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年5月1日

研究注册日期

首次提交

2026年10月30日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • FB_AF216

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.

IPD 共享时间框架

Start date: Following completion of the study and publication of the primary study results.

End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.

IPD 共享访问标准

Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.

IPD 共享支持信息类型

  • 研究方案
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅